SPOTLIGHT -
Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).
For younger patients with mid-range myopia, consider phakic IOLs
The implantable lenses can offer an advantage over laser surgery
The good, the bad and the maybe in ocular gene therapies
Promising innovations are not one-size-fits-all
Outlook Therapeutics submits UK Marketing Authorisation Application for wet AMD treatment
The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March
Going beyond the clinical setting in ophthalmic mentorship
Three leaders in glaucoma research, retina care and refractive surgery share their expertise
Keratometry and total keratometry values are similar in healthy eyes
Astigmatic values differed between K and TK readings
Reconfiguring treatment goals for paediatric myopia around ocular development
Considering ages and stages of myopia progression in a therapeutic timeline